Evidence map›Paper›PMID 35732005›Full record

ArticleMolecular pharmaceutics2022

Binding of the Dual-Action Anti-Parkinsonian Drug AG-0029 to Dopamine D

Nafiseh Ghazanfari, Aren van Waarde, Janine Doorduin, Jürgen W A Sijbesma, Maria Kominia, Martin Koelewijn, Khaled Attia, David Vállez-García, Antoon T M Willemsen, André Heeres and 4 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Nafiseh GhazanfariDepartment of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands.
Aren van WaardeDepartment of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands.
Janine DoorduinDepartment of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands.
Jürgen W A SijbesmaDepartment of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands.
Maria KominiaDepartment of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands.
Martin KoelewijnSymeres B.V., Kadijk 3, 9747 AT Groningen, The Netherlands.
Khaled AttiaDepartment of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands.
David Vállez-GarcíaDepartment of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands.
Antoon T M WillemsenDepartment of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands.
André HeeresSymeres B.V., Kadijk 3, 9747 AT Groningen, The Netherlands.
Rudi A J O DierckxDepartment of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands.
Ton J VisserSymeres B.V., Kadijk 3, 9747 AT Groningen, The Netherlands.
Erik F J de VriesDepartment of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands.
Philip H ElsingaDepartment of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands.ORCID 0000-0002-3365-4305
University Medical Center Groningen · NLFlevoziekenhuis · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

DopamineReceptors, Dopamine D3AnimalsBrainHistamineLigandsMaleMammalsPharmaceutical PreparationsPositron-Emission TomographyRacloprideRatsRats, WistarReceptors, Dopamine D2DopamineHistamineLigandsPharmaceutical PreparationsRacloprideReceptors, Dopamine D2Receptors, Dopamine D3[11C]GSK-189254[11C]racloprideanti-Parkinson drugdopamine D2 receptordual-action pharmaceuticalhistamine H3 receptorParkinson’s diseasepharmacokinetic modeling

Identifiers

PMID35732005
PMCPMC9257755
OpenAlexW4283272743

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.